Halo Biosciences Participating in BIO @ JPM and BIOTECH SHOWCASE™ During J.P. Morgan Week 2022 SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Halo Biosciences, a clinical stage biopharmaceutical company today announced that its Chief Executive Officer, Anissa Kalinowski, MSc, MBA, will...

Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and...